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Abstract
Background: Antibiotic-resistant bacteria (ARB) are selected by the use of antibiotics. The rational design of interventions
to reduce levels of antibiotic resistance requires a greater understanding of how and where ARB are acquired. Our aim
was to determine whether acquisition of ARB occurs more often in the community or hospital setting.
Methods: We used a mathematical model of the natural history of ARB to estimate how many ARB were acquired in
each of these two environments, as well as to determine key parameters for further investigation. To do this, we explored
a range of realistic parameter combinations and considered a case study of parameters for an important subset of
resistant strains in England.
Results: If we consider all people with ARB in the total population (community and hospital), the majority, under most
clinically derived parameter combinations, acquired their resistance in the community, despite higher levels of antibiotic
use and transmission of ARB in the hospital. However, if we focus on just the hospital population, under most parameter
combinations a greater proportion of this population acquired ARB in the hospital.
Conclusions: It is likely that the majority of ARB are being acquired in the community, suggesting that efforts to
reduce overall ARB carriage should focus on reducing antibiotic usage and transmission in the community setting.
However, our framework highlights the need for better pathogen-specific data on antibiotic exposure, ARB clearance
and transmission parameters, as well as the link between carriage of ARB and health impact. This is important to
determine whether interventions should target total ARB carriage or hospital-acquired ARB carriage, as the latter often
dominated in hospital populations.
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design
Background
Infections due to antibiotic-resistant bacteria (ARB) are as-
sociated with higher morbidity and mortality levels [1]. Glo-
bally, numbers of infections with ARB are increasing [2]. To
tackle ARB, we need to develop interventions that optimise
treatment outcomes whilst slowing the dissemination of
antibiotic resistance. In order to develop these interventions
we need to quantify the important transmission routes of
ARB [3] and determine how much each setting contributes
to the overall ARB burden. Without this information, we are
potentially wasting resources on poorly targeted interven-
tions [3, 4], resulting in delays in clinical care improvement
and the continued spread of ARB to potentially irreversible
levels [5].
ARB encountered in clinical situations may originate
from any setting in which bacteria are exposed to antibi-
otics [6]. Such settings include hospitals, nursing homes,
soil and wastewater from pharmaceutical plants [7, 8].
Although we know that antibiotics exist in many envi-
ronments, we do not know what proportion of infections
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caused by ARB is due to the antibiotic exposure in each
environment. For example, although a significant pro-
portion of antibiotics is used in agriculture [9], there is
an on-going debate about how much this usage selects
for ARB that are ultimately transmitted to humans [10].
We therefore cannot currently predict the likely human
health impact of reducing agricultural antibiotic use, al-
though recent modelling work suggests that reducing
transmission from livestock may be more important
[11].
In this work we focus on two broad settings: the commu-
nity and hospitals, as both are important for human ARB
acquisition [12]. We define the “community” to be the
population of individuals not in a healthcare setting. We
did not include any settings with indirect pathways to hu-
man carriage of ARB, as the estimates are currently highly
uncertain due to a lack of data (e.g. for agriculture [10]).
Although the vast majority (~ 80%) of healthcare antibi-
otics prescribed in England in 2013 were for patients in
the community [13], the per capita exposure is greater
and more infections with ARB occurred in hospitals [14].
This is worrying, as the hospital population suffer more
serious consequences. What is unknown is whether, under
a broad range of realistic parameters, ARB are commonly
being acquired within the hospital setting or in the com-
munity and repeatedly introduced into hospitals within
which they then spread. The former hypothesis suggests
that antibiotic control in the community will do little to
reduce the burden of serious ARB infections in hospitals,
whilst the latter suggests that it may be key.
To address this unknown, we present a dynamic trans-
mission mathematical model that tracks the acquisition
of ARB by humans in each setting for a range of scenar-
ios. The model structure is similar to previous modelling
work exploring ARB movement between community
and hospital settings (e.g. [12, 15–17]), but it is novel in
that it generalises to multiple pathogen/antibiotic combi-
nations to ask: Are there broad trends for acquisition
that can be found, and under what parameter conditions
are most ARB acquired in the community? Previous
modelling work has focused on invasion of community
strains into the hospital setting (e.g. [15, 18]) or mecha-
nisms which drive maintenance of resistance in hospitals
(e.g. [16, 19]). There is also a large body of work quanti-
fying the different relative contribution of various colon-
isation or transmission routes of ARB in hospital wards
[3, 4, 20–22]. This work expands on this quantification
in the hospital, to explore the contribution of the hos-
pital vs. community setting to acquisition of ARB under
a large set of parameter combinations.
With this quantification we can explore whether broad
trends exist using multiple scenarios, such as whether
we would expect most ARB to be selected in the com-
munity or in the hospital and where interventions for
ARB should be targeted. This adds to existing clinical
data, which usually only report where the patient was
when ARB carriage (asymptomatic or an infection) was
detected but cannot differentiate where or how resist-
ance was acquired: e.g. did a patient with a bloodstream
infection in a hospital ward acquire that ARB in the hos-
pital, or before, in the community? To link to a specific
example, we considered the set of parameters for a case
study of Escherichia coli resistant to third-generation
cephalosporins in England, which are an increasing
problem [23].
Our long-term aim is to quantify the sources of ARB
[24]. With this study, we explore the relative contribu-
tions of two important environments and provide the
basic structure to be expanded upon in future quantifi-
cation work. This first step demonstrates what can and
should be done for ARB research and also highlights the
gaps in our existing understanding.
Methods
To determine where humans acquire ARB, we split a
population of 100,000 people into subpopulations based
on their setting (community or hospital) and bacterial
status (with no bacteria or susceptible bacteria, or with
ARB acquired within the hospital or community) (Fig. 1).
Here “with bacteria” incorporates both carriage and in-
fection. The community setting was taken to be broadly
representative of the general population.
Within the population, people moved from the com-
munity (CX) into the hospital (HX) at the hospitalisation
rate per day (α) and exited at a rate (l). Assuming that
all hospitals are full [16], we initially set a constant per-
centage of 0.25% of the total population to be in hospital
(but varied this in sensitivity analyses). People were
grouped by their bacterial carriage status: carrying no
bacteria or susceptible bacteria (Cs, Hs), carrying ARB ac-
quired in the hospital (CRh, HRh) or carrying ARB acquired
in the community (CRc, HRc). We did not differentiate
people by age, gender, co-morbidity or colonisation/infec-
tion status. We assumed that infected and colonised
people have the same infectivity [16, 25, 26], but that those
“with” bacteria who become infected had a higher mortal-
ity rate [27].
ARB was acquired either by transmission at a rate
(βcωc/Nc, βhωh/Nh) from an exogenous source or by de
novo emergence (εωc, εωh) (Fig. 1). Here, βc, βh are the
transmission rates, ωc, ωh the antibiotic exposure rates
and Nc, Nh the population sizes in the hospital and com-
munity respectively. ε is the proportion of people who
acquire resistance during each antibiotic treatment. We
chose a frequency-dependent transmission formulation
to reflect likely transmission by the hands of healthcare
workers in the hospital setting, where the likelihood of
colonisation of the healthcare worker will depend on the
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proportion of patients carrying ARB, rather than the dens-
ity. We used the same assumption in the community for
consistency. Both acquisition rates (via transmission and
de novo emergence) were dependent on exposure to anti-
biotics, as antibiotic use clears sensitive bacterial carriage,
predisposing a host to colonisation with the (new) ARB.
Linking transmission directly to antibiotic exposure cap-
tures this impact of selection on both the source of trans-
mission (antibiotic exposure increases the ARB load) and
the receiver (antibiotic exposure increases the chance of
successful ARB transmission).
A higher transmission rate was (usually) assumed in
the hospital (some models assume all transmission oc-
curs only in hospitals, e.g. [16]). This is due to patient
proximity, increased bacterial load and a high prevalence
of immunocompromised patients in hospitals. The total
number of contacts is likely to be greater in the commu-
nity, due to the likely higher relative mobility of people
in the community; however, each contact is likely to
have a lower chance of successful bacterial transfer.
“Acquired” was defined by where the ARB were ac-
quired, regardless of from whom they were transmitted.
This is important in the public health context, as many
infections with ARB are endogenous [28, 29], and hence
knowledge of the original source of ARB acquisition is
highly important for targeting interventions to reduce
infections with ARB. The rate of transmission was taken
to be a mass action assumption with random mixing in
the hospital and community separately.
Those carrying bacteria can become infected (ic, ih)
and die (μc, μh) at a higher rate than the background
mortality rate. Due to potential fitness costs to resist-
ant strains, it was assumed that resistant strains are
equally or less likely to cause an infection than sus-
ceptible strains (by a factor rinf ) [30]. People do not
remain persistently colonised with ARB in the com-
munity, but instead carriage is lost at a rate c. Due to
the short duration of stay and the likely higher trans-
mission rates in hospital, it was assumed that resist-
ant bacterial carriage is not lost in the hospital
setting.
These bacterial and patient dynamics (Fig. 1) were
captured using a compartmental, deterministic model
(see Additional file 1). All parameter values are listed in
Table 1. Our results, as they are proportions, remain the
same for any large population size. Detailed explanations
of methods to determine the ranges for each parameter
are given in Additional file 1.
Case study
To give a specific parameter combination, we considered
a case study of E. coli in England, focusing on pheno-
typic resistance to third-generation cephalosporins,
which is commonly, but not exclusively, mediated by
production of extended-spectrum β-lactamases (ESBLs).
We chose this due to the frequent use of β-lactams in
both community and hospital settings, the existence of
mandatory surveillance data for E. coli bacteraemia and
due to the increasing problem of resistance (see
Additional file 1) [23].
Total population analysis
Our primary outcome measure was the proportion of
the total population with resistance who had acquired it
in the hospital (Eq. (1)).
CS 
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CRc 
HS 
HRh 
HRc 
Hospital (Nh ) 
Resistance generation Clearance Transmission 
Community (Nc ) 
c 
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Fig. 1 Model diagram of the community and hospital populations. Our compartmental model subdivides a human population into those in the
community (CX) and those in the hospital (HX). People move between the hospital and the community (at rates α and l) and between further
subpopulations depending on the ARB they carry and where they were acquired (X: S = susceptible, Rc = ARB acquired in the community, Rh =
ARB acquired in the hospital). ARB acquisition is dependent on setting-specific transmission rates (βc, βh), antibiotic exposure levels (ωc, ωh) and
population sizes (Nc, Nh) in the community or hospital respectively. ARB clearance occurs at a rate c
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Proportion of resistance in total population acquired in hospital
¼ HRh þ CRh
HRc þHRh þ CRc þ CRh
ð1Þ
Due to the high levels of parameter uncertainty, our
results are presented across many parameter combina-
tions to encompass many possible resistance types.
Firstly, we performed bivariate parameter analysis, with
all other parameters held at the values in the case study.
Secondly, in order to further explore multivariate effects,
we used Latin hypercube sampling (LHS) (a method by
which a well-distributed set of parameters is generated
from a multidimensional distribution) to generate 10,000
parameter sets from our parameter ranges (Table 1).
These 10,000 parameter sets allowed us to explore,
within reasonable bounds, many possible combinations
of values for each of the clinical variables in the model,
for example, high antibiotic usage in hospitals with low
lengths of patient stay and vice versa. Extreme parameter
combinations resulted in negative population sizes,
which arose due to our use of a discrete-time simulation.
We removed these values, to leave our final valid param-
eter set. With the variation in exit and entry rates, the
size of our “hospital” population varied from 0 to 4% of
the total population. This could reflect a larger hospital
population than is currently the case for England, or our
“hospital” setting representing a hospital population plus
other populations with similar characteristics (e.g. high
antibiotic exposure) such as nursing homes, where ap-
proximately 0.5% of the English population resides [31].
Using the valid LHS parameter samples we performed
a sensitivity analysis to consider which parameters drive
relative acquisition and hence should be targeted for
both interventions and further data collection. This was
done using a partial rank correlation coefficient analysis
(PRCC) [32].
Table 1 Parameter values with description and range of parameters explored as well as the values used in the case study. For all
details on calculations see Additional file 1
Symbol Parameter description Range Case study Notes and references
N Total population size 100,000 100,000 Fixed
Nh Size of the total population
in hospital
(0.02% to 3%)N 0.25% Fixed in baseline [37], explored in
sensitivity analysis
Nc Size of the total population
in the community
(1 – [0.02% to 3%])N 1–0.25% Depends on Nh
α Rate at which those in the
community enter the hospital
2 × 10−4 to 2 × 10−3 per day 8 × 10− 4 per day Linked to number of admissions
per day [38]
l Rate at which those hospitalised
return to the community
0.05 to 1 per day 0.32 per day Varied to fit Nh
b Background death rate Fixed 1/(81*365) Inverse of life expectancy [39]
ε Proportion that acquire
resistance during each antibiotic
treatment
0.0008 to 0.13 0.0135 per treatment Estimates taken from a range of
studies (see Additional file 1)
ωc Rate of antibiotic exposure
in community
(1 to 15)/1000 per day 8.6/1000 per day Using total consumption in England
in 2014 [23] and point prevalence
surveillance data [40]
ωh Rate of antibiotic exposure in hospital (0.5 to 1.00)ωc 0·22 per day
βh Transmission rate in the hospital 0.1 to 10 per day 1.8 per day Case study value calibrated [14, 41].
Assumed to be the same or lower
in the communityβc Transmission rate in the community βh/25 to 2βh βh
c Rate of clearance of resistant bacteria
in community
1/730 to 1/42 per day 1/127 per day Estimates taken from a range of studies
(see Additional file 1)
ic Rate of infection in the community (1.4 to 2.8) × 10
− 6 1.75 × 10− 6 [42]
ih Rate of infection in the hospital (5 to 500)ic 100ic Assumed to be higher in hospitals due
to patient co-morbidities.
rinf Decreased rate of infection by
resistant organisms
0.5 to 1 0.8 Most ARB have reduced fitness, which
can be ameliorated. (see Additional file 1)
μr Proportion of infections with
resistant bacteria that result
in death
0.4 to 0.9 0.6 Case study value based on
bacteraemia data [27]
μc Proportion of infections with
susceptible bacteria that
result in death
0.1 to 0·5 0.2
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Hospital population analysis
The preceding multivariate analysis was repeated for the
hospital subpopulation with a similar outcome measure:
what proportion of those with ARB in hospital had ac-
quired it in the hospital setting (Eq. (2)). This allowed us
to explore whether those in the hospital setting have a
different place of ARB acquisition than the total
population.
Proportion of resistance in hospital population acquired in hospital
¼ HRh
HRc þ HRh
ð2Þ
A sensitivity analysis was also performed for this out-
come (Eq. (2)) and for the prevalence of resistance in the
population.
Results
Analysis of the total population
The minority of human ARB acquisition in our case
study of E. coli resistant to third-generation cephalospo-
rins occurs in the hospital (5%) (targets in Fig. 2).
Under most of our parameter combinations (bivariate
and multivariate) the majority of the ARB in the total
population was acquired in the community (Fig. 2). Only
under certain scenarios was more resistance acquired in
the hospital (Fig. 2, green to blue shaded areas above the
50% cut-off dashed line). Importantly, if the rate of
transmission in the hospital is increased (y axis, Fig. 2a),
then acquisition in the hospital is greater when the level of
transmission in the community is lower by a factor of six
or more (we explored up to a factor of 25 times lower). At
extremely low transmission levels, more resistance is
acquired in the community setting, due to a reversal to de
novo resistance generation (instead of transmission) dom-
ination in the larger community population.
Even when antibiotic exposure is much higher in the
hospital than in the community setting, acquisition in
the hospital does not dominate in our model (Fig. 2b).
Similarly, even when the exit rate from hospital is ex-
tremely low (i.e. there are long lengths of stay in hospital)
or the rates of clearance of resistance in the community
are high, acquisition in the hospital does not dominate
(Fig. 2c–d). Varying the infection or mortality rates had lit-
tle impact on these results (see Additional file 1).
More of the total ARB burden was acquired in the
community under the majority (76%) of the valid (6562)
LHS parameter sets (Fig. 2e). The proportion of acquisi-
tion in the community varied by parameter set, with a
mean of 69% of ARB acquired in the community (see
Additional file 1). Similar results were seen across differ-
ent hospital population sizes (see Additional file 1).
Our sensitivity analysis showed that the most influen-
tial parameters on the proportion of ARB acquired in
the hospital are those of relative antibiotic exposure,
exit/entry rates and transmission in the hospital (Fig. 3).
Analysis of the hospital population
In the hospital population, the minority of human ARB
acquisition in our case study of E. coli resistant to
third-generation cephalosporins also occurs in the hos-
pital (35%) (targets in Fig. 4). This was an exception to
the majority of parameter scenarios, where most patients
with ARB in hospital had acquired this resistance whilst
in the hospital setting (Fig. 4). The exceptions were
when transmission in the hospital was high, and similar
in the community (Fig. 4a); when there was high anti-
biotic use in the community or similar levels in both set-
tings (Fig. 4b); and when the rate of clearance in the
community was low (Fig. 4d). Varying the exit and entry
rates from those assumed in our case study (Fig. 4c) also
generated no scenarios where most ARB in the hospital
setting were acquired in the hospital setting.
When considering only those with ARB in the hos-
pital, more had acquired them in the hospital under the
majority (78%) of the valid LHS parameter samples
(Fig. 4e). The proportion acquired in hospital varied
across parameter sets, with a mean of 71% of ARB ac-
quired in hospitals (see Additional file 1).
Our sensitivity analysis showed that the most influen-
tial parameters on the proportion of ARB acquired in
the hospital for those patients in hospital are those of
antibiotic exposure, rate of clearance of resistance in the
community and length of stay (hospital exit rate) (see
Additional file 1). For overall prevalence of resistance
(see Additional file 1), the rate at which resistance is
cleared and antibiotic exposure in the community, as
well as the proportion that acquire resistance during
antibiotic exposure are the most important parameters.
Discussion
Our work suggests that most ARB in the total popula-
tion are acquired in the community setting. If instead we
consider the small hospital subpopulation, under the
majority of parameters considered, those patients in hos-
pital with ARB had acquired them in the hospital. Quan-
titative assessment frameworks such as this can be used
to make much sought-after predictions regarding the
spread of ARB and the impact of interventions [7].
For example, this output forms part of the evidence
base required for the recommended interventions,
such as where to prioritise vaccine or diagnostic roll-
out, in the recent UK O’Neill Report on “tackling
drug-resistant infections globally” [33]. Such informa-
tion is urgently needed, as ARB is already a major
societal issue globally [2, 10].
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The key parameters that alter where resistance is acquired
are antibiotic use, length of hospital stay and the rate of
transmission of ARB. Only under scenarios of much greater
levels of transmission (Fig. 2a, upper right-hand corner) or
antibiotic use in hospitals (Fig. 2b, lower right-hand side) is
human ARB acquisition in the total population driven by
hospitals. The predominance of human acquisition of ARB
in the community is linked to the substantially higher num-
bers of people in the community (~ 98% of our population).
If we increase the percentage of the population in our “hos-
pital” setting, then the proportion acquired in hospitals in-
creases, as seen by Kouyos et al. when exploring hospital
size and ARB [17]. It is then crucial for intervention design
and our understanding of ARB that we know the details of
the heterogeneous settings in our populations and their
interrelationships.
If reducing the total acquisition of ARB is our goal,
then this model suggests interventions should target
antibiotic exposure in the community setting. There are
many ways that this could be done, for example by using
educational interventions [34] or by targeting the symp-
toms most likely to be inappropriately prescribed antibi-
otics, such as sore throat [35]. Within the hospital
setting, this model suggests that to reduce acquisition of
ARB here, interventions should target transmission (for
example by improved hand hygiene) and reduced
antibiotic exposure. More acquisition also occurs in the
hospital setting if clearance rates are higher in the com-
munity, suggesting that post-discharge decolonisation
regimes, whilst aiding in driving down resistance preva-
lence, may shift the majority of ARB acquisition from
occurring in the community to the hospital setting.
a b
c d
e
Fig. 2 The proportion of the total population with resistance that was acquired in the hospital at different parameter values. Here, red shading
indicates that the minority in the total population acquired resistance in the hospital setting under bivariate (a–d) and multivariate parameter
analysis (e). The dashed lines indicate the boundary of 50% resistance acquired in the hospital. Blue/green shaded areas indicate parameter
combinations where the majority of human acquisition was in the hospital setting. The bivariate parameter combinations were of a varying
transmission rates, b varying antibiotic exposure rates, c varying entry and exit rates into the hospital and d varying clearance and acquisition
rates. Note that for a–d all other parameters are held at their case study values. e Most people with ARB in the total population had acquired
ARB in the community setting for the majority of our LHS parameter samples. The targets (a–d) and cross (e) indicate the parameter
combinations in our case study
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Length of stay was also an important driver of where ac-
quisition occurs, which could be targeted by tackling fun-
damental infrastructure (e.g. improved outpatient care).
To understand the clinical implications of this work
we also need to consider the following question: does a
reduction in human acquisition of ARB, which we model
here, directly lead to a decrease in their associated health
burden? We found that to reduce total ARB carriage re-
quires interventions against acquisition of ARB in the
community. However, the majority of those with ARB in
hospitals had acquired them in the hospital. Although
the hospital population is very small (< 4% of the total
population), it is the one in which infection with ARB is
potentially far more serious due to the higher proportion
of people with immunocompromised status. Hence, it
could be argued that reducing ARB burden in hospitals
would have a bigger health impact. Targeting ARB in
hospitals may also have a knock-on effect if those in
hospital are the key sources of on-going transmission
due to their immunocompromised status and increased
bacterial load. Thus, the link between ARB acquisition
and impact on health burden needs to be determined.
Similarly, the routes to successful acquisition need to be
established. For example, in exploring antibiotic use in
agriculture, what proportion of those who eat meat con-
taminated with ARB subsequently become infected?
Our case study highlights that our choice of where we
target interventions should be tailored by the type of
resistance and pathogen under consideration. Here, for
E. coli resistant to third-generation cephalosporins, this
work suggests that interventions should be focused on
the community setting, as the majority of ARB acquisi-
tion (even in the hospital population) was always in the
community (crosses in Figs. 2e and 4e). This reflects the
parameters of this case study, where we assumed that
transmission rates were the same in the hospital and
community, that acquisition rates per treatment were
low and, importantly, that high levels of cephalosporins
are used in the community. For other ARB with high
levels of antibiotic exposure in the community (such as
other β-lactams) it may be that most acquisition is al-
ways in the community setting. However, for the major-
ity of our parameter combinations, and hence other
ARB, the picture is more complex, and the levels of use
of the specific antibiotic in each setting will be critically
important in determining where acquisition occurs. This
can be seen through the dependence of our results on
antibiotic exposure in the sensitivity analysis (Fig. 3).
Factor by which infection rate is higher in hospital
Death rate when infected with resistant strain
Death rate when infected with susceptible strain
Infection rate in the community
Factor by which infection rate
of resistant strains is lower
Antibiotic exposure level in the community
Rate of clearance of resistance in the community
Hospital transmission rate
Proportion acquire resistance
during each antibiotic exposure
Factor by which transmission rate
in the community is lower
Rate those in the community enter the hospital
Hospital exit rate
Factor by which antibiotic exposure
in hospital is higher
Partial Rank Correlation Coefficient
−0.4 −0.2 0.0 0.2 0.4 0.6
Fig. 3 Tornado diagram of the key drivers of resistance acquisition in hospitals from partial rank correlation coefficient analysis. The parameters
with the highest absolute values have the greatest influence on the proportion of resistance in the total population acquired in hospital
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The strengths of our study are that it uses a transpar-
ent quantitative framework to explore a broad parameter
range that encompasses a wide set of potential scenarios
for ARB acquisition. As there are few good estimates for
many of these parameters (e.g. transmission rates), this
allows for only broad conclusions to be drawn. More-
over, this model captures only a subset of the dynamics
— both important human population and environmental
stratifications are missing. Including missing human
population stratifications (e.g. age, colonisation and in-
fection status, and co-morbidities) would alter the move-
ments between settings, requiring lengths of stay and
contact pattern distributions, antibiotic exposure rates,
as well as mortality rates. In particular, it is known that
resistance prevalence is highest in those with longer
lengths of hospital stay. Environmental stratifications
could include agricultural and waste water contact.
In comparison to previous work, our analysis is novel
in that it considers acquisition of ARB from a broader,
more general quantitative perspective, namely: how
much ARB is acquired in which setting? This differs
from previous mathematical models of ARB spread in
the community and hospital [12, 16, 17, 25] which con-
sider the importance of community reservoirs and the
contribution of incoming carriage rates to their primary
focus of the hospital.
The parameter sensitivity analysis suggests that future
work should focus on determining better estimates for
a b
c d
e
Fig. 4 The proportion of the hospital population with resistance that was acquired in the hospital at different parameter values. Here, red shading
indicates that the minority in the hospital population acquired resistance in the hospital setting under bivariate (a–d) and multivariate parameter
analysis (e). The dashed lines indicate the boundary of 50% resistance acquired in the hospital. Blue/green shaded areas indicate parameter
combinations where the majority of human acquisition was in the hospital setting. The bivariate parameter combinations were of a varying
transmission rates, b varying antibiotic exposure rates, c varying entry and exit rates into the hospital and d varying clearance and acquisition
rates. Note that for a–d all other parameters are held at their case study values. e Most people with ARB in the hospital population had acquired
ARB in the hospital setting for the majority of our LHS parameter samples. The targets (a–d) and cross (e) indicate the parameter combinations in
our case study
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levels of transmission, antibiotic exposure and the rate
at which ARB are cleared. Their correlation with the
proportion of resistance acquired in the hospital
suggests that these parameters are also key targets for
interventions.
The next steps for this model would be to include the
additional structural complexities that can be parame-
terised. Specifically, the entry and exit rates for the
population should be stratified, potentially by age, as
these rates were found to be key influences on the pro-
portion of resistance acquired in hospitals. This lack of
heterogeneity is the main limitation of this model. In-
cluding further human population stratification would
likely result in acquisition differences by age (e.g. more
acquisition in the community in certain age groups than
others). The model could also be tailored to suit differ-
ent pathogens and resistance types, as the quantitative
contributions of different environments are likely to
vary. One assumption to be varied is the 100% carriage
rate, which is not true for pathogens such as Staphylo-
coccus aureus and its important resistant subpopulation
(methicillin-resistant S. aureus, MRSA). Complexity here
would need to be added in the form of assumptions
around the protective effect of prior colonisation.
Strikingly, most antibiotic resistance modelling studies
tackle only populations in the community, hospitals,
families and schools [36]. Extending our framework, for
example to build on previous work showing the likely
contribution of livestock antibiotic usage [11], could be
used to test hypotheses, evaluate trends in resistance de-
velopment over time and test the relative impact of new
interventions. Furthermore, if we could extend our
model to quantify how much ARB acquisition takes
place in different hospital settings, such as wards, then
we could potentially design better treatment options
(e.g. if little ARB acquisition occurs in intensive care
units, then last line antibiotics could be used there for
critically ill patients).
To test our model results would require new data to
be collected; for example, there could be a large pro-
spective longitudinal study, tracking where and how
people acquire ARB. This could be done by routinely
sampling an individual’s microbiome and that of his/her
environment, to determine when (if at all) and where
(community or hospital) acquisition of ARB occurs. The
study would have to be large and long (~years) to be pow-
ered to detect hospital vs. community differences due to
the low rate of hospitalisation and low prevalence of ARB.
In the absence of such a large trial, efforts to determine
differences in parameters, such as average antibiotic ex-
posure levels in community and hospital settings, could be
used to improve our parameter estimates. This would nar-
row the range of parameters explored within this model
and allow us to be more confident as to where acquisition
is occurring. Our model predictions of relative levels of
acquisition at these new estimates could then be tested by
targeting interventions either at the community or hos-
pital (whichever the model deems to be the setting of
most acquisition) and comparing impact on ARB carriage
and infection levels.
This study provides a new framework for ARB source
quantification. We need now to not focus solely on where
ARB infections are detected but on the settings where
ARB are acquired. With this knowledge we can target
ARB acquisition at its source, rather than fire fight at the
clinical endpoint. More research is crucially needed on
ARB prevalence across healthcare and environmental set-
tings, transmission routes for ARB that result in human
health burden and the levels and acquisition effects of
antibiotic usage.
Conclusions
This is the first step to building a quantitative framework
to test the relative contributions of all of the complex
multidimensional drivers of ARB acquisition and hence
improve intervention design. Here, we highlight the com-
plex relationships that are likely to be uncovered by show-
ing that, under the majority of our resistance scenarios,
although the majority of ARB acquisition occurs in the
community, most people with ARB in the hospital have
acquired it in the hospital setting. Future work needs to
develop this model to capture the full spectrum of ARB
sources and to capture data on acquisition and transmis-
sion across these source environments.
Additional file
Additional file 1: Additional information: Model equations and details
of parameterisation. Additional results: Proportion of the population in
hospital, variation in infection and mortality rates, histogram of parameter
sets, sensitivity analyses. (PDF 177 kb)
Abbreviations
ARB : Antibiotic-resistant bacteria; ESBL: Extended-spectrum β-lactamase;
LHS: Latin hypercube sampling; MRSA: Methicillin-resistant Staphylococcus
aureus; PRCC: Partial rank correlation coefficient analysis
Acknowledgements
The authors also wish to acknowledge support from the National Institute
for Health Research (NIHR) Imperial Biomedical Research Centre provided to
LSPM and AHH.
Funding
The work was supported by the NIHR Health Protection Research Unit (HPRU)
in Healthcare Associated Infections and Antimicrobial Resistance at Imperial
College London in partnership with Public Health England (PHE). The views
expressed are those of the author(s) and not necessarily those of the National
Health Service (NHS), the NIHR, the Department of Health or PHE.
Availability of data and materials
All data generated or analysed during this study are included in this
published article and its additional file.
Knight et al. BMC Medicine  (2018) 16:137 Page 9 of 11
Authors’ contributions
The concept was designed through discussions between GMK, AHH, CC and
LSPM. The modelling was performed by GMK with technical support from
SD and JVR. Results analyses and interpretation were performed by all
authors. GMK wrote the first draft. All authors read, commented on and then
approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
AHH has received an Honorarium for presenting at a conference entitled
South African Antibiotic Stewardship Programme Annual Workshop,
sponsored by Merck (MSD Hoddesdon) from Medical Services, MSD
Hoddesdon. LSPM consulted for bioMerieux in 2014 and for DNA Electronics
in 2015, held an unrelated research grant from Leo Pharma in 2016 and
received travel/meeting/accommodation expenses from Eumedica in 2016.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1National Institute of Health Research Health Protection Research Unit in
Healthcare Associated Infections and Antimicrobial Resistance, Department
of Infectious Diseases, Imperial College London, London W12 0NN, UK. 2Data
Analytics, The Health Foundation, London, UK. 3Imperial College Healthcare
NHS Trust, London, UK. 4Antimicrobial Resistance Programme, Public Health
England, London, UK. 5Royal Free London NHS Foundation Trust Healthcare,
London, UK. 6Division of Healthcare-Associated Infection & Antimicrobial
Resistance, National Infection Service, Public Health England, London, UK.
7Modelling and Economics Unit, National Infection Service, Public Health
England and Health Protection Research Unit in Modelling Methodology,
London, UK.
Received: 16 October 2017 Accepted: 9 July 2018
References
1. Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic
resistance. Clin Microbiol Infect. 2016;22(5):416–25.
2. WHO: Antimicrobial resistance: global report on surveillance. 2014.
3. Pelupessy I, Bonten MJ, Diekmann O. How to assess the relative importance
of different colonization routes of pathogens within hospital settings. Proc
Natl Acad Sci U S A. 2002;99(8):5601–5.
4. Mikolajczyk RT, Sagel U, Bornemann R, Kramer A, Kretzschmar M. A statistical
method for estimating the proportion of cases resulting from cross-
transmission of multi-resistant pathogens in an intensive care unit. J Hosp
Infect. 2007;65(2):149–55.
5. Global Antimicrobial Resistance Surveillance System (GLASS) report: early
implementation 2016–17. Geneva: World Health Organization; 2017. http://
apps.who.int/iris/bitstream/10665/259744/1/9789241513449-eng.pdf?ua=1.
Accessed July 2018.
6. Department of Health UK. Antimicrobial resistance (AMR) systems map.
2014. https://www.gov.uk/government/publications/antimicrobial-resistance-
amr-systems-map. Accessed July 2018.
7. Berendonk TU, Manaia CM, Merlin C, Fatta-Kassinos D, Cytryn E, Walsh F, et
al. Tackling antibiotic resistance: the environmental framework. Nat Rev
Microbiol. 2015;13(5):310–7.
8. Tello A, Austin B, Telfer TC. Selective pressure of antibiotic pollution on
bacteria of importance to public health. Environ Health Perspect. 2012;
120(8):1100–6.
9. UK one health report: joint report on human and animal antibiotic use,
sales and resistance. 2015. https://www.gov.uk/government/publications/
uk-one-health-report-antibiotics-use-in-humans-and-animals. Accessed July
2018.
10. Review on Antimicrobial Resistance. Tackling drug-resistant infections
globally: An overview of our work. https://amr-review.org/Publications.html.
Accessed July 2018.
11. van Bunnik BAD, Woolhouse MEJ. Modelling the impact of curtailing
antibiotic usage in food animals on antibiotic resistance in humans. R Soc
Open Sci. 2017;4:161067. https://doi.org/10.1098/rsos.161067.
12. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient,
hospitals and the community using simple mathematical models. Philos
Trans R Soc Lond Ser B Biol Sci. 1999;354(1384):721–38.
13. Ashiru-Oredope D, Hopkins S, English Surveillance Programme for
Antimicrobial Utilization and Resistance Oversight Group. Antimicrobial
stewardship: English Surveillance Programme for Antimicrobial Utilization
and Resistance (ESPAUR). J Antimicrob Chemother. 2013;68(11):2421–3.
14. Moore LS, Freeman R, Gilchrist MJ, Gharbi M, Brannigan ET, Donaldson H,
Livermore DM, Holmes AH. Homogeneity of antimicrobial policy, yet
heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility
among 108,717 clinical isolates from primary, secondary and tertiary care
patients in London. J Antimicrob Chemother. 2014;69(12):3409–22.
15. D'Agata EM, Webb GF, Horn MA, Moellering RC Jr, Ruan S. Modeling the
invasion of community-acquired methicillin-resistant Staphylococcus aureus
into hospitals. Clin Infect Dis. 2009;48(3):274–84.
16. Cooper BS, Medley GF, Stone SP, Kibbler CC, Cookson BD, Roberts JA,
Duckworth G, Lai R, Ebrahim S. Methicillin-resistant Staphylococcus aureus
in hospitals and the community: stealth dynamics and control catastrophes.
Proc Natl Acad Sci U S A. 2004;101(27):10223–8.
17. Kouyos RD, Abel Zur Wiesch P, Bonhoeffer S. On being the right size: the
impact of population size and stochastic effects on the evolution of drug
resistance in hospitals and the community. PLoS Pathog. 2011;7(4):
e1001334.
18. Hetem DJ, Westh H, Boye K, Jarlov JO, Bonten MJ, Bootsma MC. Nosocomial
transmission of community-associated methicillin-resistant Staphylococcus
aureus in Danish hospitals. J Antimicrob Chemother. 2012;67(7):1775–80.
19. van Kleef E, Luangasanatip N, Bonten MJ, Cooper BS. Why sensitive bacteria
are resistant to hospital infection control. Wellcome Open Res. 2017;2:16.
20. Bootsma MC, Bonten MJ, Nijssen S, Fluit AC, Diekmann O. An algorithm to
estimate the importance of bacterial acquisition routes in hospital settings.
Am J Epidemiol. 2007;166(7):841–51.
21. Forrester M, Pettitt AN. Use of stochastic epidemic modeling to quantify
transmission rates of colonization with methicillin-resistant Staphylococcus aureus
in an intensive care unit. Infect Control Hosp Epidemiol. 2005;26(7):598–606.
22. McBryde ES, Pettitt AN, Cooper BS, DL ME. Characterizing an outbreak of
vancomycin-resistant enterococci using hidden Markov models. J R Soc
Interface. 2007;4(15):745–54.
23. English Surveillance Programme for Antimicrobial Utilisation and Resistance
(ESPAUR) 2010 to 2014: report 2015. 2015. https://www.gov.uk/government/
publications/english-surveillance-programme-antimicrobial-utilisation-and-
resistance-espaur-report. Accessed July 2018.
24. Knight GM, Costelloe C, Murray KA, Robotham JV, Atun R, Holmes AH.
Addressing the unknowns of antimicrobial resistance: quantifying and
mapping the drivers of burden. Clin Infect Dis. 2018;66(4):612–6.
25. Kardas-Sloma L, Boelle PY, Opatowski L, Brun-Buisson C, Guillemot D,
Temime L. Impact of antibiotic exposure patterns on selection of
community-associated methicillin-resistant Staphylococcus aureus in
hospital settings. Antimicrob Agents Chemother. 2011;55(10):4888–95.
26. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the
volume of antimicrobial consumption in human communities and the
frequency of resistance. Proc Natl Acad Sci U S A. 1999;96(3):1152–6.
27. Melzer M, Petersen I. Mortality following bacteraemic infection caused by
extended spectrum beta-lactamase (ESBL) producing E. Coli compared to
non-ESBL producing E. Coli. J Infect. 2007;55(3):254–9.
28. Robinson TP, Bu DP, Carrique-Mas J, Fevre EM, Gilbert M, Grace D, Hay SI,
Jiwakanon J, Kakkar M, Kariuki S, et al. Antibiotic resistance is the quintessential
one health issue. Trans R Soc Trop Med Hyg. 2016;110(7):377–80.
29. Health matters: preventing infections and reducing antimicrobial resistance.
2017. https://www.gov.uk/government/publications/health-matters-
preventing-infections-and-reducing-amr/health-matters-preventing-
infections-and-reducing-antimicrobial-resistance. Accessed July 2018.
30. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to
reverse resistance? Nat Rev Microbiol. 2010;8(4):260–71.
31. Changes in the older resident care home population between 2001 and
2011. London: Office for National Statistics; 2014. http://webarchive.
Knight et al. BMC Medicine  (2018) 16:137 Page 10 of 11
nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/
dcp171776_373040.pdf. Accessed July 2018.
32. Iman RL, Helton JC, Campbell JE. An approach to sensitivity analysis of
computer models. Part 2. Ranking of input variables, response-surface
validation, distribution effect and technique synopsis. J Qual Technol. 1981;
13(4):232–40.
33. Review on Antimicrobial Resistance. Tackling drug-resistant infections
globally. Final report and recommendations. 2016. http://amr-review.org/.
Accessed July 2018.
34. Roque F, Herdeiro MT, Soares S, Teixeira Rodrigues A, Breitenfeld L, Figueiras
A. Educational interventions to improve prescription and dispensing of
antibiotics: a systematic review. BMC Public Health. 2014;14:1276.
35. Smieszek T, Pouwels KB, Dolk FCK, Smith DRM, Hopkins S, Sharland M, Hay
AD, Moore MV, Robotham JV. Potential for reducing inappropriate antibiotic
prescribing in English primary care. J Antimicrob Chemother. 2018;
73(suppl_2):ii36–43.
36. Opatowski L, Guillemot D, Boelle PY, Temime L. Contribution of
mathematical modeling to the fight against bacterial antibiotic resistance.
Curr Opin Infect Dis. 2011;24(3):279–87.
37. Average number of available and occupied beds open overnight by sector.
https://www.england.nhs.uk/statistics/statistical-work-areas/bedavailability-
and-occupancy/bed-data-overnight/. Accessed July 2018.
38. Hospital Episode Statistics: Admitted Patient Care, England - 2013-2014.
http://www.hscic.gov.uk/catalogue/PUB16719 . Accessed July 2018.
39. World Development Indicators. http://data.worldbank.org/country/united-
kingdom. Accessed July 2018.
40. English National Point Prevalence Survey on Healthcare-associated
Infections and Antimicrobial Use, 2011. London: Health Protection Agency;
2012.
41. Wickramasinghe NH, Xu L, Eustace A, Shabir S, Saluja T, Hawkey PM. High
community faecal carriage rates of CTX-M ESBL-producing Escherichia coli
in a specific population group in Birmingham, UK. J Antimicrob Chemother.
2012;67(5):1108–13.
42. Public Health England. Annual epidemiological commentary: mandatory
MRSA, MSSA and E. coli bacteraemia and C. difficile infection data, 2013/14.
https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-
bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary.
Accessed July 2018.
Knight et al. BMC Medicine  (2018) 16:137 Page 11 of 11
